After years of disappointing ALS clinical trial results, this year's Sheila Essey Award recipient for significant contributions in ALS research is shifting to prevention.
The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition.
A new study out of Université Laval suggests blocking inflammation could reduce symptoms in some patients living with ALS, also known as Lou Gehrig's disease.
In the last year, the FDA has approved two new drugs for ALS, after a nearly 20-year drought of new options. The approvals followed intense lobbying by advocacy.